Literature DB >> 12092861

Beyond doughnuts: tumor board recommendations influence patient care.

John K Petty1, John T Vetto.   

Abstract

BACKGROUND: There is little solid evidence to support the belief that tumor conferences directly impact the care patients receive. This study investigated the recommendations made at tumor conferences and whether these recommendations were enacted.
METHODS: Cancer registrars from Oregon-area hospitals with tumor boards that utilized a prospective "working" format were surveyed regarding tumor board characteristics and content. They also recorded the recommendations made for each prospective case presented at each tumor board for one month. Later, they contacted each patient's provider to see which recommendations had been implemented.
RESULTS: Information from eight tumor boards in six hospitals was recorded. The institutions varied with regard to size, location, number of tumor boards, number of cases reviewed annually, and types of cancers reviewed. One hundred fifty-three specific, prospective recommendations were made for the care of 97 patients. Of these, 128 (84%) were followed, 2 (1%) were pending, and 5 (3%) were status unknown. Of recommendations followed, 21 (16%) were for diagnosis, 100 (78%) were for therapy, and 7 (5%) were for palliation.
CONCLUSION: Recommendations made at tumor conferences are generally implemented into patient care. Tumor boards can play a strategic role in the planning of care for cancer patients.

Entities:  

Mesh:

Year:  2002        PMID: 12092861     DOI: 10.1080/08858190209528807

Source DB:  PubMed          Journal:  J Cancer Educ        ISSN: 0885-8195            Impact factor:   2.037


  33 in total

1.  Multidisciplinary treatment of head and neck cancer.

Authors:  Prashanth Varkey; Yi-Tien Liu; Ngian Chye Tan
Journal:  Semin Plast Surg       Date:  2010-08       Impact factor: 2.314

2.  Innovation: Tumour board--introducing real time to oncology management.

Authors:  Timothy Craig Allen; Bryan A Liang
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

3.  Evaluation of the tumor board as a Continuing Medical Education (CME) activity: is it useful?

Authors:  Maryclare Sarff; Wendy Rogers; Charles Blanke; John T Vetto
Journal:  J Cancer Educ       Date:  2008 Jan-Mar       Impact factor: 2.037

4.  Multidisciplinary management of cancer patients: chasing a shadow or real value? An overview of the literature.

Authors:  J M Croke; S El-Sayed
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

5.  Tumor boards: beyond the patient care conference.

Authors:  Abdul Rahman Jazieh
Journal:  J Cancer Educ       Date:  2011-09       Impact factor: 2.037

6.  Role of a multidisciplinary clinic in the management of patients with pancreatic cysts: a single-center cohort study.

Authors:  Anne Marie Lennon; Lindsey L Manos; Ralph H Hruban; Syed Z Ali; Elliot K Fishman; Ihab R Kamel; Siva P Raman; Atif Zaheer; Susan Hutfless; Ashley Salamone; Vandhana Kiswani; Nita Ahuja; Martin A Makary; Matthew J Weiss; Kenzo Hirose; Michael Goggins; Christopher L Wolfgang
Journal:  Ann Surg Oncol       Date:  2014-05-08       Impact factor: 5.344

Review 7.  Lung cancer in elderly patients.

Authors:  Federico Venuta; Daniele Diso; Ilaria Onorati; Marco Anile; Sara Mantovani; Erino A Rendina
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

8.  Tumor board: more than treatment planning--a 1-year prospective survey.

Authors:  Troy A Gatcliffe; Robert L Coleman
Journal:  J Cancer Educ       Date:  2008       Impact factor: 2.037

9.  Integrating Palliative Care Into Comprehensive Cancer Centers: Consensus-Based Development of Best Practice Recommendations.

Authors:  Julia Berendt; Stephanie Stiel; Steffen T Simon; Andrea Schmitz; Birgitt van Oorschot; Peter Stachura; Christoph Ostgathe
Journal:  Oncologist       Date:  2016-07-20

10.  The need for assessment and reassessment of the hospital cancer conference.

Authors:  Frederick L Greene
Journal:  Ann Surg Oncol       Date:  2009-07-28       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.